Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
1,343 results
  • Effect of the number of dose adjustment factors on bleeding risk in patients receiving 30 mg/day edoxaban. [Journal Article]
    J Clin Pharm Ther 2019Takase T, Ikesue H, … Hashida T
  • CONCLUSIONS: This is the first study to evaluate the risk of bleeding in patients administered 30 mg/day of edoxaban based on the number of dose adjustment factors in clinical practice. For patients receiving edoxaban, as the number of the dose adjustment factors increases, the risk of major bleeding is elevated. In patients with multiple dose adjustment factors, not only one level of dose reduction, but further dose reductions may be considered. Further studies with a larger sample size are needed to confirm these findings.
  • Treatment Failures of Direct Oral Anticoagulants. [Journal Article]
    Am J Ther 2019Kajy M, Mathew A, Ramappa P
  • CONCLUSIONS: Our analysis illustrates that DOACs may fail in the setting of Food and Drug Administration and non-Food and Drug Administration- approved indications. In clinical practice, it may be best to choose between available anticoagulant drugs on a case-by-case basis.
  • Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial. [Journal Article]
    Circulation 2019Bergmark BA, Kamphuisen PW, … Giugliano RP
  • CONCLUSIONS: Among patients with AF at risk for stroke, there was an approximately four-fold difference in the frequency of the most severe bleeding events across commonly used bleeding scales. Further, the relative safety of edoxaban as compared with warfarin tended to increase with greater severity of bleeding. Clinical Trial Registration: URL: Unique Identifier: NCT00781391.
  • The continuous challenge of antithrombotic strategies in diabetes: focus on direct oral anticoagulants. [Review]
    Acta Diabetol 2019Pomero F, Dentali F, … Mastroiacovo D
  • Direct oral anticoagulants (DOACs) include dabigatran, which inhibits thrombin, and apixaban, edoxaban, and rivaroxaban, which inhibit factor Xa. They have been extensively studied in large trials involving patients affected by the most common cardiovascular diseases. As the presence of diabetes leads to peculiar changes in primary and secondary hemostasis, in this review we highlight the current…
New Search Next